Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

 
• By Sarah Karlin-Smith

Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.

sign that reads "false"
Promoting clinical benefits of an interchangeable over standard biosimilars is likely to be considered false and misleading by the FDA. • Source: Shutterstock

More from Marketing & Advertising

More from Compliance